Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack.
Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.
Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.